Veros™ COVID-19 Produces Highly Accurate Molecular Results in about 15 minutes BOSTON & OXFORD, England & CAMBRIDGE, England & TORONTO--(BUSINESS WIRE)--Global molecular diagnostics innovator Sense Biodetection (Sense) today announced it has entered in
Appili completes strategic reprioritization of programs to focus on ATI-1701, a biodefense tularemia vaccine candidate, ATI-1801, a topical antiparasitic product for the treatment of a disfiguring disease, and ATI-1501, a liquid oral formulation of the a
The pneumococcal conjugate vaccine is designed to broaden protection against life-threatening childhood pneumonia and other serious pneumococcal diseases. REDMOND, Wash.--(BUSINESS WIRE)--Biotechnology company Inventprise today announced that a Phase 1/2
Trial met its primary endpoint with Onivyde® (irinotecan liposome injection) in the NALIRIFOX treatment regimen showing statistically significant improvement in overall survival compared to nab-paclitaxel plus gemcitabine regimen Study met key second
Continued strong revenue growth of 15.7% vs. prior year to $229.7 million Gross margin expanded 190 basis points to 13.7% Net loss from continuing operations of $12.6 million, including $14.2 million net loss from asset dispositions Adjusted EBITDA
Early Phase 1 clinical data readout for RP-6306 is expected in the first half of 2023 Advancing camonsertib development with Roche under worldwide license and collaboration agreement IND-enabling studies for RP-2119, a Polθ inhibitor, currently underw
New version of ICH reduces notification fatigue with a near perfect false positive rejection rate; and allows medical teams to make faster decisions for improved hemorrhage management SAN MATEO, Calif.--(BUSINESS WIRE)--RapidAI, the global leader in neur
WINNIPEG, Manitoba--(BUSINESS WIRE)--Ag Growth International Inc. (“AGI”) (TSX: AFN) is pleased to announce the appointments of Rohit Bhardwaj and Paul Householder as Directors of AGI. “We are thrilled to have Rohit and Paul join our Board. We are
WINNIPEG, Manitoba--(BUSINESS WIRE)--Ag Growth International Inc. (TSX: AFN) (“AGI”, the “Company”, “we” or “our”) today announced its financial results for the three- and nine-month periods ended September 30, 20221. Three-months
Announced exclusive license agreement with Jazz Pharmaceuticals to develop and commercialize zanidatamab, Zymeworks’ lead clinical candidate, for total potential payments of up to $1.76 billion, plus royalties on net sales Hosted Early Research and
Sign up for one of BAM's newsletter to learn more about bioscience, happenings in Manitoba's bioeconomy, industry conferences, and BAM training events.